Sorrento Therapeutics, Inc. (SRNE) is a clinical-stage biopharmaceutical company developing new cancer treatment therapies. It's also developing potential antiviral therapies and vaccines against COVID-19. The company has an extensive portfolio of immuno-oncology platforms, including clinical stage immuno-cellular therapies (CAR-T, DAR-T), and antibody-drug conjugates (ADCs). (See Sorrento stock charts on TipRanks) Encouraging immune response for DYAI-100 It was announced on Thursday that preclinical vaccination studies of Sorrento's COVID-19 vaccination candidate, DYAI-100, indicated strong neutralizing immune responses in animals vaccinated against SARS-CoV-2, and other major variants of the virus.
https://www.tipranks.com/news/article/will-sorrentos-promising-covid-19-vaccine-results-boost-stock?utm_source=advfn.com&utm_medium=referral
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Sorrento Therapeutics Charts.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Sorrento Therapeutics Charts.